Association of rituximab use with adverse events in adults with lymphoma or autoimmune disease: a single center experience

作者：Mengsi Hu, Tingwei Zhang, Bing Liu, Qi Guo, Bing Zhao, Jiangong Lin, Zhimei Lv, Rong Wang · 发表于：Frontiers in Medicine · 年份：2025 · DOI：10.3389/fmed.2025.1567886 · 被引用次数：6 · 研究领域：Renal Diseases and Glomerulopathies、Systemic Sclerosis and Related Diseases、Lymphoma Diagnosis and Treatment

Objective Rituximab (RTX) is a chimeric human/murine CD20 monoclonal antibody, which has been administered in treating hematological malignancies and various autoimmune disorders. This study aimed to present our center’s experience in RTX use in adults with lymphoma and autoimmune diseases (AID) including primary membranous nephropathy (pMN), as well as therapeutic effects of RTX on clinical outcome of pMN patients. Methods A total of 761 Chinese patients were retrospectively included, who received RTX treatment at Shandong Provincial Hospital between January 1st, 2017 and December 31st, 2021, with person time of exposure spanning between their first dose of RTX and last follow-up date or the end of the study period. Results Adverse events (AEs) occurred in 487 patients (64.0%), with a majority of infection (309, 40.6%) and a minority of non-infectious AEs (178, 23.4%); and the incidences of AEs were higher in lymphoma patients (381, 65.8%) than that in AID patients (106, 58.2%). Respiratory infections (215, 28.3%), gastrointestinal infections (49, 6.4%), urinary tract infections (41, 5.4%), cutaneous and mucosal infections (31, 4.1%), and infections in the abdominal cavity or pleurisy (4, 0.5%) were the leading types of infections. Cancer diagnosis [hazard ratio (HR), 3.926; 95% confidence interval (CI), 1.730–8.913] and prophylactic sulfamethoxazole/trimethoprim (SMZ/TMP) administration (HR, 3.793; 95% CI, 1.101–13.069) were associated with increased risk of infections. Imm...